lx4

LX-4 is a selective activator of the p38 mitogen-activated protein kinase (MAPK) pathway. LX-4 de-represses a subset of endogenous genes repressed by DNA methylation.

GLX481304 is a selective Nox-2 and Nox-4 inhibitor, exhibiting IC50 values of 1.25 μM. It inhibits ROS production in isolated mouse cardiomyocytes and enhances their contractility. This compound is useful in research focused on ischemic cardiac injury [1].

GLX481369 is a redox-active substance that functions as an NOX4 inhibitor, exhibiting antioxidant effects [1].

Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.

Bomedemstat ditosylate (IMG-7289 ditosylate) is an orally active lysine-specific demethylase 1 (LSD1) inhibitor with antitumor activity that potentiates the response to PD-1 inhibition in a homozygous model of SCLC, inhibits cancer cell proliferation, and induces apoptosis. Bomedemstat ditosylate can be used to study myeloproliferative neoplasms and myelofibrosis.

PLX-4720 is a potent and selective B-Raf (V600E) inhibitor designed to block the ATP-binding site of oncogenic B-Raf with IC50 of 13 nM.

LX-4211 intermediate is a synthetic intermediate of LX-4211, a potent SGLT1/2 inhibitor used as an antidiabetic agent.

(S,S)-PLX-4545 (Compound I) is an orally active cereblon-based molecular glue degrader targeting IKZF2 (zinc finger transcription factor Helios). It is useful for studying diseases or conditions mediated by IKZF2, such as proliferative disorders and/or cancer.

Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.

KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.

KD026-metabolite, is a metabolite of KD-026. KD026, also known as SLx-4090, is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.

Xanthalin is a non-alkaloid natural compound of Angelica purpurascens (Avé-Lall.) Gilli. (Apiaceae) with cholinesterase and carbonic anhydrase inhibition potential.

Tivumecirnon (FLX475) is a selective and orally active CCR4 antagonist that inhibits the infiltration and migration of regulatory T cells (Tregs) into the tumour microenvironment, exhibiting antitumour activity.

Plx-4032 (Vemurafenib) is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.

PLX-4545 has oral biological activity and is a cereblon based IKZF2 (zinc finger transcription factor Helios) molecular gel degrading agent that acts on immune suppressive regulatory T cells, reprogramming them into pro-inflammatory effector T cells and enhancing anti-tumor immune response.

Alx40-4C trifluoroacetate is a chemokine receptor (CXCR4) inhibitor, which inhibits the binding of sdf-1 to CXCR4.Alx40-4ctrifluoroacetate was also an APJ receptor antagonist with an IC50 value of 2.9 M.

ALX40-4C is a small peptide inhibitor of the chemokine receptor CXCR4 that can inhibit X4 strains of HIV-1.

ALX 40-4C acetate is a CXCR4 inhibitor of the chemokine receptor (Ki = 1 μM) and suppresses the replication of X4 strains of HIV-1. ALX 40-4C acetate is an antagonist of the APJ receptor (IC50 = 2.9 μM).